May 06, 2025

Weight Loss, Hypokalemia Reveal Pituitary Cushing’s Disease

A 75-year-old woman with severe weight loss and low potassium was diagnosed with pituitary Cushing’s disease, challenging assumptions about how the condition typically presents.

Conexiant

May 01, 2025

FDA Approves Intranasal DHE for Acute Migraine Relief

The FDA has approved Atzumi for the acute treatment of migraine with or without aura in adults.

Conexiant

April 29, 2025

New Oral Option Approved for GCA

The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.

Conexiant

April 28, 2025

One Third Report HPPD After Psychedelics

Delusional ideation was found to be reduced one month after psychedelic use, researchers reported in a prospective cohort of 654 participants.

Conexiant

April 23, 2025

Dry Eye Treatment May Quell Migraine Severity

Longer and larger studies are still needed for a full picture of connections between the conditions

Conexiant

April 22, 2025

Heavy Metals Found in Toothpaste

There are some "heavy metals that are essential in small quantities but could result in adverse effects if present in excess."

Conexiant

April 21, 2025

New Prescription App Reduces Migraine Days

The FDA has authorized CT-132, the first prescription digital therapeutic for episodic migraine prevention, based on clinical trial data showing reduced monthly migraine days.

Conexiant

April 17, 2025

We Want Your Perspective!

Join our roster of respected specialists and share your clinical perspectives.

Conexiant

April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant